Trastuzumab-Associated Dermatomyositis

Waheed, Saadia; Zubair, Hafiz Muhammad; Waheed, Farishta; Iqbal, Shumaila Muhammad

doi:10.1097/00045391-900000000-98564

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another uncommon adverse event is carotenoderma, also referred to as carotenosis cutis, and aurantiasis cutis refers to the manifestation of yellow-orange skin coloration resulting from carotenemia ( 41 ). There have also been reported cases of trastuzumab induced dermatomyositis, a complement-mediated idiopathic inflammatory myopathy manifested by skin changes and proximal muscle weakness ( 42 ).…”

Section: Targeted Therapy and Immunotherapymentioning

confidence: 99%

Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers

et al. 2021

View full text Add to dashboard Cite

Treatment of head and neck cancers requires multidisciplinary collaboration to reduce morbidity and mortality associated with the tumor burden, as well as to preserve function of organs and structures. With the use of various new targeted therapies come new adverse events including dermatologic toxicities, which may consist of xerosis, nail and hair changes, morbilliform or papulopustular rashes, to more severe eruptions such as Stevens–Johnson syndrome. We describe the dermatologic toxicities and corresponding grades of severity and associated pathophysiology resulting from seven therapeutics used to treat head and neck cancers: cetuximab, trastuzumab, pembrolizumab, nivolumab, lentatinib, larotrectinib, and entrectinib. Being familiar with these dermatologic toxicities allows clinicians to provide comprehensive counseling for patients, encourage preventative measures, and to know when it is appropriate to hold therapy or permanently stop treatment.

show abstract

Section: Targeted Therapy and Immunotherapymentioning

confidence: 99%